Stocks
Merck Hit With Ruling on Medicare Price Negotiation Program
A federal judge in Washington D.C. has ruled against Merck, dismissing its challenge to the Inflation Reduction Act's Drug Price Negotiation Program.
The program aims to lower Medicare and Medicaid prescription costs by allowing the U.S. government to negotiate prices with pharmaceutical companies like Merck.
The ruling on August 24, 2026, comes after Merck argued that its voluntary participation in the program was sufficient to meet the requirements of the law.